|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.99 USD | -1.09% |
|
+3.77% | +7.65% |
| Capitalization | 539.21Cr 461.73Cr 429.39Cr 400.32Cr 748Cr 49TCr 802.29Cr 4.95TCr 1.94TCr 23TCr 2.02TCr 1.98TCr 85TCr | P/E ratio 2025 * |
56.4x | P/E ratio 2026 * | 25.2x |
|---|---|---|---|---|---|
| Enterprise value | 722.66Cr 618.81Cr 575.47Cr 536.52Cr 1TCr 65TCr 1.08TCr 6.63TCr 2.61TCr 31TCr 2.71TCr 2.65TCr 1,14200Cr | EV / Sales 2025 * |
6.23x | EV / Sales 2026 * | 5.75x |
| Free-Float |
53.57% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Sotera Health Company
| 1 day | -1.09% | ||
| 1 week | +3.77% | ||
| Current month | +7.65% | ||
| 1 month | +12.83% | ||
| 3 months | +23.71% | ||
| 6 months | +60.93% | ||
| Current year | +7.65% |
| 1 week | 18.44 |  | 19.85 |
| 1 month | 16.55 | | 19.85 |
| Current year | 17.54 | | 19.85 |
| 1 year | 9.53 | | 19.85 |
| 3 years | 9.53 | | 19.85 |
| 5 years | 5.78 | | 30.38 |
| 10 years | 5.78 | | 30.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Petras
CEO | Chief Executive Officer | 58 | 01/06/2016 |
Jon Lyons
DFI | Director of Finance/CFO | 49 | 26/06/2023 |
Robert Hauzie
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Petras
CHM | Chairman | 58 | 01/10/2020 |
Sean Cunningham
BRD | Director/Board Member | 50 | 01/10/2020 |
Ann Klee
BRD | Director/Board Member | 64 | 01/05/2020 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.09% | +3.77% | +44.85% | +3.88% | 545.46Cr | |
| +0.48% | -0.73% | +56.63% | +85.90% | 11TCr | |
| +0.07% | -0.07% | +67.38% | -9.89% | 10TCr | |
| +3.03% | +6.35% | +46.84% | +78.59% | 3.23TCr | |
| +2.75% | +6.79% | -12.93% | +19.05% | 2.37TCr | |
| -0.56% | -1.10% | +7.93% | -0.77% | 2.09TCr | |
| +0.86% | +1.41% | +15.91% | +18.78% | 1.94TCr | |
| -0.79% | -3.57% | +55.98% | +290.24% | 1.77TCr | |
| -0.07% | +0.51% | +57.94% | +53.30% | 1.7TCr | |
| -0.52% | -7.59% | +12.59% | +40.89% | 1.29TCr | |
| Average | +0.42% | +0.28% | +35.31% | +58.00% | 3.59TCr | |
| Weighted average by Cap. | +0.55% | +0.21% | +47.44% | +50.61% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 116.09Cr 99Cr 92Cr 86Cr 161.04Cr 10TCr 172.73Cr 1.06TCr 418.61Cr 5.01TCr 435.36Cr 426.43Cr 18TCr | 122.79Cr 105.14Cr 98Cr 91Cr 170.33Cr 11TCr 182.7Cr 1.13TCr 442.76Cr 5.29TCr 460.48Cr 451.04Cr 19TCr |
| Net income | 9.92Cr 8.5Cr 7.9Cr 7.37Cr 14Cr 894.52Cr 15Cr 91Cr 36Cr 427.94Cr 37Cr 36Cr 1.57TCr | 22Cr 19Cr 18Cr 16Cr 31Cr 2TCr 33Cr 203.43Cr 80Cr 956.16Cr 83Cr 81Cr 3.51TCr |
| Net Debt | 183.45Cr 157.09Cr 146.09Cr 136.2Cr 254.48Cr 17TCr 272.95Cr 1.68TCr 661.49Cr 7.91TCr 687.97Cr 673.86Cr 29TCr | 166.59Cr 142.65Cr 132.66Cr 123.68Cr 231.1Cr 15TCr 247.87Cr 1.53TCr 600.72Cr 7.18TCr 624.76Cr 611.95Cr 26TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/26/12 | 18.98 $ | -1.15% | 21,33,370 |
| 09/26/09 | 19.20 $ | +2.07% | 56,89,217 |
| 08/26/08 | 18.81 $ | +0.05% | 14,10,777 |
| 07/26/07 | 18.80 $ | +0.37% | 14,62,102 |
| 06/26/06 | 18.73 $ | +2.35% | 24,20,115 |
Delayed Quote Nasdaq, January 13, 2026 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SHC Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition